# Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer

## TL;DR

This review discusses strategies to overcome resistance to immunotherapy in small-cell lung cancer, focusing on new treatments and clinical trials.

## Contribution

The paper provides a comprehensive overview of emerging therapeutic strategies to address immunotherapy resistance in small-cell lung cancer.

## Key findings

- Immunotherapy resistance in SCLC is influenced by tumor heterogeneity and an immunosuppressive microenvironment.
- New approaches like antibody-drug conjugates and adoptive cell therapies are being tested to overcome resistance.
- Combination therapies and bi-specific antibodies show promise in preclinical and clinical studies.

## Abstract

Small-cell lung cancer is one of the deadliest malignancies worldwide. Resistance mechanisms to immunotherapy remain a limitation to clinical benefit. Combination therapies and innovative drugs are being tested, also in clinical trials, and new therapeutic strategies pave the way to overcome resistance to immunotherapy. In this review, we discuss preclinical and clinical evidence of these strategies.

Small-cell lung cancer (SCLC) is the most lethal histologic subtype of lung cancer. It is characterized by rapid tumor growth and early metastatic dissemination, resulting in an extremely poor prognosis. The addition of immunotherapy to standard chemotherapy has led to a modest improvement in survival for patients with extensive-stage disease. However, the overall clinical benefit remains limited due to both primary and acquired resistance to immunotherapy. Indeed, the efficacy of immune checkpoint inhibitors is influenced by multiple factors, including tumor heterogeneity, an immunosuppressive tumor microenvironment, and intrinsic molecular characteristics of the disease. In recent years, active research has been conducted to identify and therapeutically overcome resistance mechanisms to immunotherapy, and accumulating suggestive evidence is lighting the way for new strategies for clinical management of patients with SCLC. In this review article, we summarize and discuss the substantial obstacle to immunotherapy clinical efficacy, with a particular emphasis on the published and ongoing clinical trials that investigated the potential strategies to overcome mechanisms of resistance to immunotherapy. Moreover, we report and discuss the new therapeutic approaches tested, especially the use of antibody–drug conjugates, bi-specific antibodies, adoptive cell therapies and combination strategies.